Currentculinary health fundPolicy N/A

Susvimo (ranibizumab intravitreal implant) — Coverage Criteria

Policy governs coverage and utilization management for Susvimo (ranibizumab intravitreal injection via ocular implant) for ophthalmologic indications; affects providers seeking prior authorization or coverage from Culinary Health Fund.

Policy Summary

Payerculinary health fund

PolicySusvimo (ranibizumab intravitreal implant) — Coverage Criteria

Policy CodePolicy N/A

Change TypeAdded indications to Not Recommended for Approval

Effective DateN/A

Next Review DateN/A

Key ActionDo not submit requests expecting approval; Susvimo is not recommended for approval due to safety concerns and requests are likely to be denied.

SourceLink

POLICY UPDATE CHANGES

Diabetic Macular Edema was added to the Conditions Not Recommended for Approval section.

Diabetic Retinopathy was added to the Conditions Not Recommended for Approval section.

Boxed WarningSafety warning for endophthalmitis

1.7% vs 0.5%Endophthalmitis rate (AMD active)

2%Endophthalmitis (AMD pooled)

No approvalOverall coverage stance

Coverage Criteria and Policy Stance

Not Recommended for Approval — Indication-specific

Susvimo is not recommended for approval for the following ophthalmic indications due to safety concerns (Boxed Warning for endophthalmitis and higher observed ocular adverse events):

Diabetic Macular Edema: Coverage of Susvimo for DME is not recommended due to safety data including the Boxed Warning for endophthalmitis and higher rates of other ocular adverse events; although Susvimo demonstrated non-inferior efficacy to monthly intravitreal ranibizumab in the pivotal DME trial, the safety profile precludes recommendation for approval.

See pivotal trial safety findings and boxed warning; endophthalmitis incidence in AMD active comparator period 1.7% vs 0.5% and 2% when extension phases included.

Diabetic Retinopathy: Coverage of Susvimo for diabetic retinopathy is not recommended due to safety data including the Boxed Warning for endophthalmitis and higher overall ocular adverse events; despite efficacy signals in trial populations, observed safety risks outweigh benefits and preclude recommendation for approval.

See trial safety data and boxed warning; when including extension phases, 2% of Susvimo patients experienced endophthalmitis.

Neovascular (Wet) Age-Related Macular Degeneration: Coverage of Susvimo for neovascular (wet) AMD is not recommended due to an increased frequency of ocular adverse events and a Boxed Warning for endophthalmitis; although efficacy was equivalent to monthly intravitreal ranibizumab in pivotal trials, the safety profile requires regular monitoring and does not support approval.

In the active comparator period, endophthalmitis rate was 1.7% for Susvimo vs. 0.5% for monthly ranibizumab; 2% when extension phases included.

Coverage of Susvimo is limited to the statements in this policy. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria; requests that do not meet the specific recommended criteria should be considered not recommended for approval. Criteria will be updated if new published data become available.

The policy’s non-coverage stance is driven by safety concerns documented in the product labeling and clinical trials. Susvimo carries a Boxed Warning for endophthalmitis, and trial data showed higher rates of endophthalmitis and other ocular adverse events with Susvimo compared with monthly intravitreal ranibizumab (e.g., an active-comparator endophthalmitis rate of 1.7% vs. 0.5%, and pooled extension-phase rates around 2%). These safety signals underlie the recommendation that Susvimo approval is not recommended across its indicated ophthalmic uses.

Actions Providers Must Take / Authorization Notes

Prior Authorization

Prior authorization criteria

Prior authorization: None — the policy lists no prior authorization or approval criteria for Susvimo. Providers should be aware that there is no automated or recommended authorization pathway documented; if seeking coverage, submit full clinical rationale and supporting documentation per payer-specific prior authorization processes.

Automation: None

Step Therapy

Step therapy not defined

Step therapy not defined: Susvimo is listed as not recommended for approval and no step therapy or required trial of alternative therapies is provided in the policy. Providers should not expect an established step-therapy path for Susvimo; consider conventional intravitreal VEGF inhibitors (e.g., ranibizumab) per standard treatment algorithms.

Denial Risk

Denial risk due to safety

Denial risk due to safety: Approval of Susvimo is not recommended because of significant safety concerns, including a Boxed Warning for endophthalmitis and higher observed rates of endophthalmitis and other ocular adverse events versus intravitreal ranibizumab in trials. Expect a high likelihood of coverage denial for Susvimo based on these safety risks.

Boxed Warning: endophthalmitis
Reported endophthalmitis rates in AMD trials: Susvimo 1.7% vs. ranibizumab 0.5%; overall up to ~2% when extensions included
Associated implant-related risks: conjunctival erosion/retraction, retinal detachment, implant dislocation, vitreous hemorrhage

Documentation Required

Supportive documentation available

Support with prescribing information: Prescribers and reviewers should reference the Susvimo prescribing information and available safety data when preparing clinical justification or appeals. Detailed trial safety outcomes, boxed warning language, and implant/procedure-related precautions are documented in the manufacturer labeling and supporting clinical publications.

Prescribing information and safety data available to prescribers/reviewers
Key trial safety findings summarized in policy (see Safety section)

Background and Clinical Context

Susvimo is an intravitreal ocular implant formulation of ranibizumab (a vascular endothelial growth factor [VEGF] inhibitor) intended to deliver ranibizumab over time rather than by repeated intravitreal injection. In pivotal trials Susvimo demonstrated efficacy comparable to monthly intravitreal ranibizumab for neovascular (wet) age-related macular degeneration and noninferiority in a DME trial, and it showed activity in diabetic retinopathy studies. Unlike standard intravitreal ranibizumab injections, the implant formulation is associated with implant-related risks and a higher observed incidence of serious ocular adverse events. The product labeling includes a Boxed Warning for endophthalmitis, and trial data reported increased rates of endophthalmitis and other ocular adverse events compared with monthly intravitreal ranibizumab, which has informed the policy’s safety-based coverage stance.

Key Terms and Definitions

Susvimo — brief identity and descriptor

Generic nameRanibizumab intravitreal implant (Susvimo)

Drug classVascular endothelial growth factor (VEGF) inhibitor

Route and formulationIntravitreal implant (distinct from intravitreal injection)

Indications listed in product labelingDiabetic macular edema (DME); Diabetic retinopathy; Neovascular (wet) age‑related macular degeneration (AMD) — in patients who previously responded to ≥2 intravitreal VEGF inhibitor injections.

Key distinguishing featureDelivered as a surgically placed ocular implant rather than standard intravitreal injections

Endophthalmitis — definition, importance, and boxed warning

DefinitionEndophthalmitis: a severe intraocular infection observed as an adverse event in Susvimo trials, occurring after implant or implant‑related procedures.

Regulatory warningBoxed Warning: Susvimo has a Boxed Warning for endophthalmitis (unique among the VEGF inhibitors).

Observed incidence (AMD active comparator period)Susvimo 1.7% vs monthly intravitreal ranibizumab 0.5% (3‑fold higher in trials).

Observed pooled incidence (including extension phases)2.0% (11/555) of patients receiving Susvimo experienced endophthalmitis; events reported between Days 5–853 (median 173 days).

Associated implant-related findingsMany events were associated with conjunctival retraction or erosion; other implant-related risks include retinal detachment, implant dislocation, vitreous hemorrhage, and conjunctival erosion/retraction.